Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules
Brief pharmaceutical news items for April 2008.

Pharmaceutical Technology


PII Opens Development and Aseptic Facility

Pharmaceutics International (PII, Hunt Valley, MD) opened a new 30,000-ft2 , state-of-the-art development, aseptic filling, and manufacturing facility. The new Beaver Court complex complements the three existing PII facilities in Hunt Valley and those of Pharmaterials (Reading, UK).

PII's development work has moved to dedicated manufacturing space in the new building. The area consists of multiple manufacturing and containment suites to perform development projects. This area will support projects before they enter production.

The aseptic facility provides vial filling for clinical supplies and niche commercial manufacturing. The filling line will initially fill small molecules and is designed to fill containment and high-potency products. A 60-ft2 lyophilizer was installed and qualified to produce lyophilized products.

People
Bilcare NamesNew CEO

Bilcare Global Clinical Supplies (Pune, India), a provider of clinical-trial materials, appointed Vito Mangiardi, a 30-year industry veteran, as its new CEO. Mangiardi most recently served as president of North American Operations for AAI Pharma (Wilmington, NC), where he was responsible for Phase I services, formulation development, analytical development, bioanalytical, manufacturing, and stability testing, as well as Phase II–IV clinical trials.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here